anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the last hundred years there has been a great improvement in the physical care of pregnant women, with a corresponding decline in morbidity and mortality for both mother and child. This same is not true of their psychological and psychiatric care in pregnancy, and this is arguably one of the most important unmet aspects of current obstetrics. Previous research has shown that if a mother has high levels of depression or anxiety during pregnancy, including in later gestation,her child is at about double the risk for ADHD(attention deficit hyperactivity disorder), conduct disorder and emotional problems later in development, as well as increased risk for cognitive delay. Prenatal stress, depression and anxiety contribute an estimated 10-15% of the variance in these outcomes. High levels of antenatal anxiety and depression are frequently co-morbid and have been shown to increase risk for preterm delivery, low birth weight, as well as being a major risk factor for postpartum depression and recurrent maternal depression. This in turn, is also associated with increased risk of long-term emotional and behavioral problems in children.

Over 80% of pregnant women with depression are currently undiagnosed and untreated. Most women prefer non pharmacological treatments during gestation and NICE(National Institute for Health and Care Excellence) clinical guidelines recommend Cognitive Behavioral Therapy (CBT) for the treatment of these disorders at this time. CBT has been shown to be effective for the treatment of depression in general; however there have been no randomized controlled trials with pregnant women. Since they may respond differently, they need to be studied directly. The most cost effective way of delivering personalized CBT is internet based and it can be offered online, individually and in real time. Computerized CBT programs have been developed to improve accessibility, but are inflexible, difficult to adapt to patient's specific needs and are associated to low rates of adherence. So, due to the real need of more accessible psychological therapies in primary care, it is crucial to investigate the efficacy of relatively low cost therapeutic tools to improve and broaden individual patient care in pregnancy.
This study is an open labeled, single-center randomized controlled trials. Patients who underwent upper enoscopy with biopsy were randomly assigned to medication and control group. In the medication group, sodium alginate was administered after EGD during 3 days. All patients underwent a questionnaire to check the presence of gastrointestinal symptoms at baseline and on the day after return home. After 3 days, gastrointestinal symptoms were investigated by telephone survey. Gastrointestinal symptom was scaled by upper gastrointestinal symptom rate score (GSRS). Upper GSRS contains 8 items and 3 scales; abdominal pain (abdominal pain, epigastric pain/hunger soreness, nausea), reflux symptom (Heartburn/reflux/belching gas), indigestion symptom (abdominal distension, borborygmus).
<P>PROBLEM TO BE SOLVED: To provide a combined drug for attaining three principles of non-illness, health, and vitality to maintain life up to 100 years old.  <P>SOLUTION: HARP-A comprises a chondroitin sulfate sodium salt, γ-linoleic acid, an aged garlic extract, a placenta extract, and vitamin B<SB>6</SB>. Alternatively, HARP-B comprises a chondroitin sulfate sodium salt, γ-linoleic acid, an aged garlic extract, and vitamin B<SB>6</SB>. HARP-KK further comprises an oyster shell powder heat treated for acceleration of absorption and an oyster extract. These drugs are administered with performing dietetic therapy and kinesitherapy. The above drugs are effective as preventive agents for cancer, cerebral infarction, myocardial infarction and the like. The drugs also have GH secretion acceleration, a biological defense effect against foreign substances and the like and can thereby construct a more healthy biological tissue structure and can achieve the reinforcement of the immune function.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Loss-of-function mutations in the tumour suppressor APC are an initial step in intestinal tumorigenesis1,2. APC-mutant intestinal stem cells outcompete their wild-type neighbours through the secretion of Wnt antagonists, which accelerates the fixation and subsequent rapid clonal expansion of mutants3-5. Reports of polyclonal intestinal tumours in human patients and mouse models appear at odds with this process6,7. Here we combine multicolour lineage tracing with chemical mutagenesis in mice to show that a large proportion of intestinal tumours have a multiancestral origin. Polyclonal tumours retain a structure comprising subclones with distinct Apc mutations and transcriptional states, driven predominantly by differences in KRAS and MYC signalling. These pathway-level changes are accompanied by profound differences in cancer stem cell phenotypes. Of note, these findings are confirmed by introducing an oncogenic Kras mutation that results in predominantly monoclonal tumour formation. Further, polyclonal tumours have accelerated growth dynamics, suggesting a link between polyclonality and tumour progression. Together, these findings demonstrate the role of interclonal interactions in promoting tumorigenesis through non-cell autonomous pathways that are dependent on the differential activation of oncogenic pathways between clones.
General anesthesia: No premedication will be applied. In the waiting room, 10 mL/kg of Ringer's lactate solution will be infused IV in 30 minutes. In Group I, 2-2.5 mg/kg propofol and 1 μg/kg fentanyl IV will be given for induction; 0.6 mg/kg rocuronium will then be used to provide the muscle relaxation needed for intubation. After intubation, the tidal volume will be set to 6-8 mL/kg and the respiratory frequency PetCO2 32-36 mmHg in volume-controlled ventilation (VCV) mode. Anesthesia will continue to be provided with sevoflurane (1.5%-2%), oxygen-air mixture (FiO 2 = 0.4) and repeated doses of rocuronium (0.015 mg/kg). At the end of the surgery, neostigmine (2-2.5 mg) and atropine (1 mg) will be given IV to antagonize the residual neuromuscular block.
<P>PROBLEM TO BE SOLVED: To provide an evening primrose-derived urease inhibitory composition having high urease inhibitory activity and high in safety as well.  <P>SOLUTION: The urease inhibitory composition comprises a solvent extract of evening primrose. Preferably, this composition comprises a solvent extract of evening primrose seeds, desirably defatted evening primrose seeds. In this composition, the solvent extract is preferably an aqueous ethanol extract desirably 40-90%(wt/wt) in ethanol concentration. This composition is preferably to be used as a material for foods/drinks or medicines.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The subjects will be prescribed a new medication as appropriate for normal therapy. This group will receive no biweekly feedback nor require to report online, but will see the endocrinologist every 3 months up to 6 months.
PURPOSE:A preventing agent for carious teeth containing at least one of 1-hexanol, cyclohexanol, etc. as an active constituent. CONSTITUTION:A preventing agent for carious teeth prepared by incorporating 0.002-5wt%, preferably 0.1-2wt%, at least one of compounds shown in the table as an active constituent with a composition for the oral cavity. A dentifrice, e.g. toothpaste, troche, mouthwash, solid mouth refrigerant, liquid mouth refrigerant, chewing gum or embrocation, etc. may be cited as the composition for the oral cavity. A dentinereinforcing agent, e.g. sodium monofluorophosphate, a germicide, e.g. chlorohexidine, an anti-inflammatory agent, e.g. dihydrocholesterol, a tissue activating agent, e.g. hinokitiol, and lysozyme or common salt as the active constituent may be incorporated with the composition.
The lethal dose in pediatric patients is not known. The lethal dose in adults is estimated to be 2 to 5 grams. The initial symptoms are nystagmus, ataxia, and dysarthria. Other signs are tremor, hyperreflexia, lethargy, slurred speech, blurred vision, nausea, and vomiting. The patient may become comatose and hypotensive. Death is due to respiratory and circulatory depression.

There are marked variations among individuals with respect to phenytoin plasma levels where toxicity may occur. Nystagmus, on lateral gaze, usually appears at 20 mcg/mL, ataxia at 30 mcg/mL; dysarthria and lethargy appear when the plasma concentration is over 40 mcg/mL, but as high a concentration as 50 mcg/mL has been reported without evidence of toxicity. As much as 25 times the therapeutic dose has been taken to result in a serum concentration over 100 mcg/mL with complete recovery.
Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule. As of 05 October 2018, the dose and schedule for Part 1 Dose Expansion Phase was selected based on all available safety, efficacy and pharmacodynamic data from the Part 1 Dose Escalation Phase. Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses less than (\<) 10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A in combination with pembrolizumab.
Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
The present invention relates to methods for the stratification of individuals suffering from cancer. In particular, the present invention relates to the finding that PTA-fragments allow the discrimination of cancer cells being susceptible to an anti-endocrine therapy from cancer cells not susceptible to said therapy. Thus, PTA-fragments can be a surrogate for estradiol receptor detection by immune histology, can be a marker to monitor resistance of cancer cells towards anti-estradiol therapy, can be used to monitor rezidives and can be used to determine the status of dedifferentiation, e.g. the state of cancer cells. PTA-fragments have the advantage to be determined from easily accessible patient samples such as serum or plasma. The present invention further encompasses specific PTA peptides and nucleic acids, antibodies therefore, test kits and diagnostic and therapeutic methods and compositions.
The minimally invasive anterior surgical approach was carried out using a modified Smith-Petersen access as described by Bender et al. (Bender et al. 2009) with the patient in supine position.
Embodiments provide a system for delivering a Cosmetic Agent (CA) into skin. The system includes a power source and at least two Electrode Assemblies (EAs) that are attachable or otherwise incorporated into a mask assembly that fits the face of a user. Each EA is configured to remain in contact with the face or other skin layers. Further, each EA includes an electrode coupled to the power source to receive an output current from the power source. At least one of the EAs in the pair includes a CA carrying medium disposed on the at least one electrode assembly to enable the output current to deliver the cosmetic agent into the epidermis, dermis, or other layer of the skin. Embodiments are particularly useful for delivering CA into selected layers of the skin to produce a desired cosmetic effect.
In both the Phase I and Phase IIa portions of the study, subjects will be evaluated for response every 8 weeks after EF-009 wafer implantation for up to 2 years, by CT, PET/CT or MRI (per treating investigator's discretion) using the same method as at baseline. Tumor measurements will be assessed based on the Response Evaluation Criteria in Solid Tumors guidelines version 1.1 (RECIST v1.1). The total study duration for each subject consists of screening, treatment, and extended follow-up period and survival follow-up period.
<P>PROBLEM TO BE SOLVED: To provide a gel sheet for cosmetic packing, having improved moisture retention of a leached solution without lowering leaching property of the solution from a gel surface, solving a problem of so-called dripping phenomenon to drip the solution and stain a garment in use, and giving sufficient contact feeling in use and effective feeling (moisture retaining feeling) by impregnation of water, etc., to a pasted skin after use.  <P>SOLUTION: The gel sheet for cosmetic packing at least contains a synthetic polymer having a network structure, a hydroxypropyl guar gum, a humectant, a polyoxyethylene methyl glucoside as a leaching agent (solution leaching promoting agent) and water, wherein the amount of the hydroxypropyl guar gum is 0.05-3 pts.wt. and that of the polyoxyethylene methyl glucoside is 3-12 pts.wt. based on 100 pts.wt. of the gel sheet.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Living with chronic pain is associated with substantial suffering and high societal costs. Patient reported outcomes (PROM's) and cellular ageing should be considered in pain management. The aim of this study was to explore correlations of PROM's and cellular ageing (telomere length [TL] and telomerase activity [TA]) amongst patients with chronic non-malignant pain. This was an explorative pilot study with cross-sectional design and recruitment was done at two pain rehabilitation facilities in Sweden, with inpatient setting/integrative care and outpatient setting/multimodal care, respectively. Eighty-four patients were enrolled by referral to pain rehabilitation in Sweden. The main outcome measures collected after admission in addition to TL and TA were the following PROMs: Numerical Rating Scale (NRS), Chronic Pain Acceptance Questionnaire (CPAQ), Hospital Anxiety and Depression Scale (HADS), Five Facets Mindfulness Questionnaire (FFMQ), WHO Quality of Life-Spiritual, Religious and Personal Beliefs (WHOQoL-SRPB) and EuroQol 5 Dimensions (EQ-5D). All the PROM's showed evidence of poor overall health status among the participants. TL correlated negatively with HADS score (r = -.219, p = .047) and positively with WHOQoL-SRPB (r = .224, p = .052). TL did not correlate with any of the pain measures. TA correlated positively with pain spread (r = .222, p = .049). A mediation of the direct effect of spiritual well-being on TL by anxiety and depression could be shown (b = 0.008; p = .045). The correlations between TL and SRPB and anxiety and depression suggest some importance of emotional and SRPB dimensions in pain management, with implications for cellular aging, which may warrant further study. Trial registration: ClinicalTrials.gov Identifier: NCT02459639.
The present invention relates to an attenuated swine fever virus live marker vaccine strain and an oral administration vaccine composition using the same. More specifically, the present invention relates to an attenuated swine fever virus live marker vaccine strain (CSFV BErns attenuated C-P50) obtained by successively and continuously culturing a conventional swine fever virus vaccine strain, Flc-LOM-BErns, between cells; an oral administration vaccine composition including the same; and a method for serologically discerning a swine fever virus outdoor infected swine and a swine in which the attenuated swine fever virus live marker vaccine strain is inoculated. The attenuated swine fever virus live marker vaccine strain, CSFV BErns attenuated C-P50, according to the present invention has alleviated side effects of pseudo acid in a pregnant mother swine, which have been a problem of a conventional swine fever virus vaccine strain, so safety is reinforced. Moreover, the oral administration vaccine composition according to the present invention is made into bait dosage forms, so a swine can easily consumed the same. Accordingly, a problem of a conventional swine fever virus vaccine used only as an injection agent and having been difficult to be administrated in fierce bush pigs and black pigs has been solved. Furthermore, through the method according to the present invention, antigens and antibodies of a swine fever virus outdoor infected swine and a swine in which the attenuated swine fever virus live marker vaccine strain, CSFV BErns attenuated C-P50, is inoculated can be discerned, so effects of differentiating infection in vaccinated animals (DIVA) are excellent.
Participants will receive bortezomib intravenously on day 1,4,8 and 11 followed by 10 days of rest. CC-5013 will be given orally on days 1-14 followed by 7-days of rest. One cycle lasts 21 days.
Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks. Participants will also receive concurrent treatment with bevacizumab every 3 weeks for 24 weeks.
The impact of sex on allergic bronchopulmonary aspergillosis (ABPA) outcomes remains uncertain. We retrospectively included ABPA subjects per the revised International Society for Human and Animal Mycology ABPA working group criteria over 13 years. We compared the clinical features, lung function, immunological tests, imaging, and ABPA exacerbation rates between men and women. Our primary objective was to assess whether women experience higher ABPA exacerbations than men. We included 731 ABPA subjects (mean age, 34.5 years; 49.5% women). Women with ABPA were older and had underlying asthma more frequently than men. There was no difference in lung function, immunological investigations, and imaging between men and women. ABPA exacerbations occurred in a slightly higher proportion of women than men (44.5% vs. 38.2%) but did not reach statistical significance (p = 0.09). We did not find a significant sex difference in ABPA exacerbation rates. Prospective studies should confirm our findings.
The study consists of two complementary trials, denoted as Part A and Part B. In Part A, women/girls who had a positive test for chlamydia will be enrolled when they visit the study clinics for treatment. After written informed consent is obtained, women will be randomly assigned to the Clinic Group, in which they will be advised to return to the clinic for rescreening for chlamydia, or the Home Group, in which women will be asked to collect a vaginal swab at home and mail it to the study laboratory for chlamydia testing. In part B, women who were tested and empirically treated for a chlamydial infection will be called if their tests were positive. Enrollment will be offered over the phone after verbal consent. Rescreening will be scheduled 3 months after treatment of the initial infection for women in both trials.
Micronized dispersible ferric pyrophosphate (MDFP) is an iron compound that has been reported to be highly bioavailable and likely to cause few sensory problems when added to food. It is therefore a potentially effective iron additive for the food industry and is particularly formulated for adding to liquids. A randomized cross-over trial will be undertaken to compare the absorption of iron added to a commercial apple juice drink as MDFP with iron added as ferrous sulphate. The null hypothesis is that absorption of iron added as MDFP is not different to absorption from iron added as ferrous sulphate.

The study population will consist of 16 women (age 18-65) with iron stores at the lower end of the normal range. This group will efficiently absorb bioavailable iron and will be sensitive to differences in bioavailability between different forms of iron. Test drinks containing added iron, labelled with stable isotopes of iron (Fe-57 or Fe-58), will be consumed on two consecutive days. Iron absorption from the drinks will be determined using the erythrocyte incorporation technique. A baseline blood sample will be taken prior to consuming the test drinks and then a second blood sample will be taken 14 days after the last test drink. Iron absorption will be calculated from the isotopic enrichment of the final blood sample, assuming that 80% of absorbed iron is incorporated into red blood cells. The order in which the volunteers will be given the MDFP or ferrous sulphate will be randomised.
Background: Sleep disturbances, including insomnia, sleep-disordered breathing, and circadian rhythm disorders with potential consequences including excessive daytime somnolence and worsening fatigue, are prevalent yet largely under-measured and therefore under-managed problems in people receiving palliative care. This has the potential to negatively affect the person's functioning and quality of life. Objectives: We aimed to review the current practice of assessment and management of sleep disturbances in people with life-limiting illnesses in Australian and New Zealand palliative care settings, and to define areas for improvement in assessment and management of sleep disturbances and further research. Design: A cross-sectional, online survey was conducted with palliative care health professionals (PCHPs) to explore current approaches to routine assessment of sleep disturbances and PCHPs' awareness of, and perceived access to, evidence-based resources for assessing and managing sleep disturbances in their local settings. Results: Fifty-four PCHPs responded to the survey, including allied health professionals (44%), palliative care nurses (26%), and physicians (19%). Over 70% of PCHPs endorsed routine verbal screening of sleep symptoms, and >90% recommended management with basic behavioral strategies. However, none of PCHPs used validated patient-reported outcome measures for sleep, and <10% of PCHPs demonstrated awareness or use of sleep-specific interventions (including medications). Only 40% reported they had access to sleep specialist services for patients. Conclusion: Our findings provide a useful snapshot of current approaches to managing sleep disturbances in palliative care. Gaps in current practice are highlighted, including the lack of structured, clinical assessment, referral pathways, and PCHPs' perceived lack of access to targeted interventions for sleep disturbances.